UBS ASSET MANAGEMENT AMERICAS INC - ADAPTIVE BIOTECHNOLOGIES COR ownership

ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS INC ownership history of ADAPTIVE BIOTECHNOLOGIES COR
ValueSharesWeighting
Q3 2023$933,543
-14.0%
171,292
+39.4%
0.00%
-100.0%
Q2 2023$1,085,3560.0%122,9170.0%0.00%0.0%
Q1 2023$1,085,356
+26.6%
122,917
+9.6%
0.00%
Q4 2022$857,100
-99.9%
112,186
+2.2%
0.00%
Q3 2022$781,271,000
-9.2%
109,729
+3.1%
0.00%
Q2 2022$860,776,000
-63.9%
106,400
-38.0%
0.00%
-100.0%
Q1 2022$2,382,405,000
-45.3%
171,643
+10.5%
0.00%
-50.0%
Q4 2021$4,359,346,000
-15.0%
155,358
+3.0%
0.00%0.0%
Q3 2021$5,125,692,000
-15.5%
150,800
+1.6%
0.00%
-33.3%
Q2 2021$6,063,870,000
-46.0%
148,406
-46.8%
0.00%
-40.0%
Q1 2021$11,237,414,000
-31.6%
279,121
+0.5%
0.01%
-37.5%
Q4 2020$16,423,771,000
+37.6%
277,757
+13.1%
0.01%
+33.3%
Q3 2020$11,938,227,000
+5.1%
245,491
+4.6%
0.01%
-14.3%
Q2 2020$11,355,367,000
+539.2%
234,712
+267.0%
0.01%
+600.0%
Q1 2020$1,776,420,000
+16.4%
63,946
+25.3%
0.00%0.0%
Q4 2019$1,526,608,000
-3.7%
51,023
-0.5%
0.00%0.0%
Q3 2019$1,585,262,000
-34.4%
51,303
+2.6%
0.00%
-50.0%
Q2 2019$2,415,000,00050,0000.00%
Other shareholders
ADAPTIVE BIOTECHNOLOGIES COR shareholders Q4 2020
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 2,377,665$12,958,27412.23%
Eagle Health Investments LP 1,214,860$6,620,9871.46%
Matrix Capital Management Company, LP 11,572,590$63,070,6160.76%
Aristotle Atlantic Partners, LLC 3,058,206$16,667,2230.67%
VIKING GLOBAL INVESTORS LP 29,993,708$163,465,7090.66%
Pier Capital, LLC 719,067$3,918,9150.63%
DDD Partners, LLC 783,697$3,385,5710.49%
ARK Investment Management 11,509,308$62,725,7280.48%
Nikko Asset Management Americas, Inc. 6,570,939$35,680,1990.43%
Triatomic Management LP 102,889$560,7450.39%
View complete list of ADAPTIVE BIOTECHNOLOGIES COR shareholders